Polymorphism in the tumor necrosis factor-alpha gene promoter is associated with severity of rheumatoid arthritis in the Czech population
Jazyk angličtina Země Německo Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- dospělí MeSH
- frekvence genu MeSH
- genetické markery MeSH
- lidé středního věku MeSH
- lidé MeSH
- polymorfismus délky restrikčních fragmentů * MeSH
- promotorové oblasti (genetika) * MeSH
- průzkumy a dotazníky MeSH
- revmatoidní artritida krev diagnóza genetika MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- stupeň závažnosti nemoci MeSH
- synoviální tekutina metabolismus MeSH
- TNF-alfa genetika metabolismus MeSH
- zdravotní stav MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Česká republika MeSH
- Názvy látek
- genetické markery MeSH
- TNF-alfa MeSH
Rheumatoid arthritis (RA) is a model of multigenic inflammatory disorder in which tumor necrosis factor-alpha (TNF-alpha) plays an important role. Genetic factors may be implicated in the susceptibility to disease initiation as well as in severity of disease course. Elevated levels of TNF-alpha in the plasma and synovial fluid from RA patients may be associated with polymorphisms in the promoter region of the TNF-alpha gene. The aim of this study was to elucidate putative association between the -308 G/A polymorphism in the promoter region of the TNF-alpha gene and susceptibility to onset and severity of RA. A total of 130 RA patients and a control group of 150 healthy subjects with similar age and sex distribution were available for the study. All patients fulfilled the American College of Rheumatology revised criteria for RA. RA patients had a disease duration of at least 2 years. Radiographs of both hands of all RA patients were scored with the Steinbrocker method. There were 15 patients of stage I (nonerosive form) of RA and 114 patients of stages II-IV (erosive form). To assess the RA patient's functional ability, the Health Assessment Questionnaire (HAQ) was used. The -308 G/A promoter polymorphism of the TNF-alpha gene was detected by polymerase chain reaction and restriction fragment length polymorphism analysis. No differences in genotype distribution and allelic frequences of -308 G/A TNF-alpha promoter polymorphism have been found between RA patients and the control group. Significant differences have been observed within the RA group divided according to the radiographic progression of disease based on the Steinbrocker radiographic score and functional ability (HAQ). These results suggest an association of the -308 G/A polymorphism of the TNF-alpha gene with the severity of RA.
Zobrazit více v PubMed
Lancet. 1999 Dec 4;354(9194):1932-9 PubMed
Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3195-9 PubMed
Arthritis Rheum. 2004 Jan;50(1):63-71 PubMed
N Engl J Med. 2000 Nov 30;343 (22):1594-602 PubMed
Genomics. 2001 Feb 1;71(3):263-70 PubMed
Tissue Antigens. 1999 Aug;54(2):194-7 PubMed
Hum Immunol. 2001 Nov;62(11):1191-9 PubMed
Arthritis Rheum. 1995 Jan;38(1):44-8 PubMed
Mol Immunol. 1997 Apr;34(5):391-9 PubMed
Tissue Antigens. 1998 Oct;52(4):359-67 PubMed
Adv Immunol. 1994;56:389-466 PubMed
Arthritis Rheum. 2003 Jan;48(1):35-45 PubMed
Arthritis Rheum. 2000 Jan;43(1):30-7 PubMed
Scand J Rheumatol. 2005;34(1):22-6 PubMed
Nat Genet. 1999 Jun;22(2):145-50 PubMed
J Inflamm. 1995-1996;46(1):32-41 PubMed
Arthritis Rheum. 1998 Sep;41(9):1552-63 PubMed
Scand J Immunol. 1999 Mar;49(3):278-85 PubMed
Dis Markers. 1995 Mar;12(2):127-33 PubMed
Rheumatology (Oxford). 2007 Jan;46(1):93-6 PubMed
Eur J Immunol. 1993 Jan;23(1):224-31 PubMed
Ann Rheum Dis. 1995 Jul;54(7):601-3 PubMed
Annu Rev Immunol. 1992;10:411-52 PubMed
J Rheumatol. 2002 Feb;29(2):212-9 PubMed
Proc Natl Acad Sci U S A. 1990 Feb;87(3):1233-7 PubMed
Ann Rheum Dis. 1987 May;46(5):395-7 PubMed
Rheumatol Int. 2000;19(4):137-40 PubMed
Ann Rheum Dis. 2004 Mar;63(3):280-4 PubMed
Crit Care Med. 1996 Mar;24(3):381-4 PubMed
Rheumatol Int. 2006 Dec;27(2):157-61 PubMed
Am J Hum Genet. 1999 Aug;65(2):294-301 PubMed
Clin Exp Immunol. 1997 Mar;107(3):507-12 PubMed
J Rheumatol. 1997 Nov;24(11):2106-12 PubMed
Curr Opin Pharmacol. 2003 Jun;3(3):280-5 PubMed
Arthritis Rheum. 1998 May;41(5):778-99 PubMed
Neurosci Lett. 1996 Sep 6;215(2):75-8 PubMed
Hum Genet. 1996 Jun;97(6):813-8 PubMed
Am J Hum Genet. 2002 Sep;71(3):585-94 PubMed
N Engl J Med. 1999 Jan 28;340(4):253-9 PubMed
Arthritis Rheum. 1988 Mar;31(3):315-24 PubMed
Arthritis Rheum. 2003 Jul;48(7):1849-52 PubMed
J Autoimmun. 2005 Feb;24(1):63-8 PubMed
J Med Genet. 1999 Mar;36(3):214-6 PubMed
Hum Immunol. 2001 Jan;62(1):75-84 PubMed
Arthritis Rheum. 2002 Jun;46(6):1443-50 PubMed
Rheumatology (Oxford). 2003 May;42 Suppl 2:ii11-6 PubMed
Curr Opin Rheumatol. 1998 May;10(3):187-200 PubMed
Br J Rheumatol. 1997 May;36(5):516-21 PubMed
Ann Rheum Dis. 2002 Nov;61 Suppl 2:ii70-3 PubMed
Arthritis Rheum. 2004 Jul;50(7):2122-9 PubMed
Tissue Antigens. 1997 Jan;49(1):74-8 PubMed
J Rheumatol. 1986 Oct;13(5):899-902 PubMed